Skip to main content
. Author manuscript; available in PMC: 2023 Feb 16.
Published in final edited form as: Circ Res. 2023 Jan 24;132(4):432–448. doi: 10.1161/CIRCRESAHA.122.322096

Figure 4. Effect of Mmp12 deletion on aortic wall complement deposition.

Figure 4.

Figure 4.

A, B. Representative images of immunofluorescence staining and quantification of C3 deposits (red) in suprarenal abdominal aorta of Apoe−/− and Mmp12−/−/Apoe−/− (A), and wild type (WT) and Mmp12−/− (B) mice. Nuclei are stained with DAPI in blue. n = 5 per group. Scale bar: 500 μm. C, D. Plasma C3 and C5a levels of Apoe−/− and Mmp12−/−/Apoe−/− (C), and WT and Mmp12−/− (D) mice. n = 5 to 10 per group. E, F. Plasma C3 levels in Mmp12−/−/Apoe−/− (E) and Mmp12−/− (F) mice at baseline and 9 days of treatment with IgG-FH1–5 or MOPC antibody (control). n = 5 per group. G, H. Representative images of immunofluorescence staining and quantification of C3 (red) in suprarenal abdominal aorta of Mmp12−/−/Apoe−/− (G) and Mmp12−/− (H) mice after 9 days of treatment with IgG-FH1–5 or MOPC antibody (control). n = 5 per group; Scale bar: 500 μm. I, J. Representative images of immunofluorescence staining and quantification of Cit-H3 (red) in suprarenal abdominal aorta of Mmp12−/−/Apoe−/− (I) and Mmp12−/− (J) mice after 9 days of treatment with IgG-FH1–5 or MOPC antibody (control). n = 4 to 5 per group. Scale bar: 500 μm. *P < 0.05, **P < 0.01, ****P < 0.0001 by two-tailed Mann-Whitney U test (A-J).